Literature DB >> 26990975

Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival.

Arjen H G Cleven1, Ghadah A Al Sannaa2, Inge Briaire-de Bruijn1, Davis R Ingram2, Matt van de Rijn3, Brian P Rubin4, Maurits W de Vries5, Kelsey L Watson6, Keila E Torres6, Wei-Lien Wang2, Sjoerd G van Duinen1, Pancras C W Hogendoorn1, Alexander J Lazar2, Judith V M G Bovée1.   

Abstract

Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas that can show overlapping features with benign neurofibromas as well as high-grade sarcomas. Additional diagnostic markers are needed to aid in this often challenging differential diagnosis. Recently mutations in two critical components of the polycomb repressor 2 (PRC2) complex, SUZ12 and EED, were reported to occur specifically in MPNSTs while such mutations are absent in neurofibromas, both in the setting of neurofibromatosis (NF) and sporadic cases. Furthermore, both SUZ12 and EED mutations in MPNSTs were associated with loss of H3K27 tri-methylation, a downstream target of PRC2. Therefore, we tested whether H3K27me3 immunohistochemistry is useful as a diagnostic and prognostic marker for MPNSTs. We performed H3K27me3 immunohistochemistry in 162 primary MPNSTs, 97 neurofibromas and 341 other tumors using tissue microarray. We observed loss of H3K27me3 in 34% (55/162) of all MPNSTs while expression was retained in all neurofibromas including atypical (n=8) and plexiform subtypes (n=24). Within other tumors we detected loss of H3K27me3 in only 7% (24/341). Surprisingly, 60% (9/15) of synovial sarcomas and 38% (3/8) of fibrosarcomatous dermatofibrosarcoma protuberans (DFSP) showed loss of H3K27 trimethylation. Only 1 out of 44 schwannomas showed loss of H3K27me3 and all 4 perineuriomas showed intact H3K27me3. Furthermore, MPNSTs with loss of H3K27 tri-methylation showed inferior survival compared with MPNSTs with intact H3K27 tri-methylation, which was validated in two independent cohorts. Our results indicate that H3K27me3 immunohistochemistry is useful as a diagnostic marker, in which loss of H3K27me3 favors MPNST above neurofibroma. However, H3K27me3 immunohistochemistry is not suitable to distinguish MPNST from its morphological mimicker synovial sarcoma or fibrosarcomatous DFSP. Since loss of H3K27 tri-methylation was related to poorer survival in MPNST, chromatin modification mediated by this specific histone seems to orchestrate more aggressive tumour biology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26990975      PMCID: PMC4948583          DOI: 10.1038/modpathol.2016.45

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  21 in total

1.  TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies.

Authors:  Jefferson Terry; Tsuyoshi Saito; Subbaya Subramanian; Cindy Ruttan; Cristina R Antonescu; John R Goldblum; Erinn Downs-Kelly; Christopher L Corless; Brian P Rubin; Matt van de Rijn; Marc Ladanyi; Torsten O Nielsen
Journal:  Am J Surg Pathol       Date:  2007-02       Impact factor: 6.394

2.  Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma.

Authors:  Zuzanna Baranski; Tijmen H Booij; Anne-Marie Cleton-Jansen; Leo S Price; Bob van de Water; Judith V M G Bovée; Pancras C W Hogendoorn; Erik H J Danen
Journal:  J Pathol       Date:  2015-03-30       Impact factor: 7.996

3.  Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumors and cellular schwannomas.

Authors:  Melike Pekmezci; David E Reuss; Angela C Hirbe; Sonika Dahiya; David H Gutmann; Andreas von Deimling; Andrew E Horvai; Arie Perry
Journal:  Mod Pathol       Date:  2014-09-05       Impact factor: 7.842

4.  Sox10 and S100 in the diagnosis of soft-tissue neoplasms.

Authors:  Jason R Karamchandani; Torsten O Nielsen; Matt van de Rijn; Robert B West
Journal:  Appl Immunohistochem Mol Morphol       Date:  2012-10

5.  Differential expression of S100 protein subtypes in malignant melanoma, and benign and malignant peripheral nerve sheath tumors.

Authors:  Daisuke Nonaka; Luis Chiriboga; Brian P Rubin
Journal:  J Cutan Pathol       Date:  2008-06-10       Impact factor: 1.587

6.  Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome.

Authors:  Changye Zou; Kerrington D Smith; Jun Liu; Guy Lahat; Sarah Myers; Wei-Lien Wang; Wei Zhang; Ian E McCutcheon; John M Slopis; Alexander J Lazar; Raphael E Pollock; Dina Lev
Journal:  Ann Surg       Date:  2009-06       Impact factor: 12.969

7.  Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST.

Authors:  Carlos N Prieto-Granada; Thomas Wiesner; Jane L Messina; Achim A Jungbluth; Ping Chi; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2016-04       Impact factor: 6.394

8.  Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors.

Authors:  Ming Zhang; Yuxuan Wang; Sian Jones; Mark Sausen; Kevin McMahon; Rajni Sharma; Qing Wang; Allan J Belzberg; Kaisorn Chaichana; Gary L Gallia; Ziya L Gokaslan; Greg J Riggins; Jean-Paul Wolinksy; Laura D Wood; Elizabeth A Montgomery; Ralph H Hruban; Kenneth W Kinzler; Nickolas Papadopoulos; Bert Vogelstein; Chetan Bettegowda
Journal:  Nat Genet       Date:  2014-10-12       Impact factor: 38.330

9.  HDAC8, A Potential Therapeutic Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors (MPNST).

Authors:  Gonzalo Lopez; Kate Lynn J Bill; Hemant Kumar Bid; Danielle Braggio; Dylan Constantino; Bethany Prudner; Abeba Zewdu; Kara Batte; Dina Lev; Raphael E Pollock
Journal:  PLoS One       Date:  2015-07-22       Impact factor: 3.240

10.  PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors.

Authors:  William Lee; Sewit Teckie; Thomas Wiesner; Leili Ran; Carlos N Prieto Granada; Mingyan Lin; Sinan Zhu; Zhen Cao; Yupu Liang; Andrea Sboner; William D Tap; Jonathan A Fletcher; Kety H Huberman; Li-Xuan Qin; Agnes Viale; Samuel Singer; Deyou Zheng; Michael F Berger; Yu Chen; Cristina R Antonescu; Ping Chi
Journal:  Nat Genet       Date:  2014-09-21       Impact factor: 38.330

View more
  56 in total

1.  Significance of H3K27me3 loss in the diagnosis of malignant peripheral nerve sheath tumors.

Authors:  Melike Pekmezci; Areli K Cuevas-Ocampo; Arie Perry; Andrew E Horvai
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  Comparision of New Diagnostic Tools for Malignant Peripheral Nerve Sheath Tumors.

Authors:  Ayca Ersen; Melike Pekmezci; Andrew L Folpe; Tarik Tihan
Journal:  Pathol Oncol Res       Date:  2016-10-12       Impact factor: 3.201

Review 3.  What's new in nerve sheath tumors.

Authors:  Anders Meyer; Steven D Billings
Journal:  Virchows Arch       Date:  2019-11-09       Impact factor: 4.064

Review 4.  Molecular profiling of sarcomas: new vistas for precision medicine.

Authors:  Tariq Al-Zaid; Wei-Lien Wang; Neeta Somaiah; Alexander J Lazar
Journal:  Virchows Arch       Date:  2017-06-29       Impact factor: 4.064

5.  Sporadic Neurofibroma of the Tongue Unassociated with Neurofibromatosis Type I: A Clinicopathologic Study of Ten Cases.

Authors:  Lester D R Thompson; Stephen S Koh; Sean K Lau
Journal:  Head Neck Pathol       Date:  2019-05-20

Review 6.  How Technology Is Improving the Multidisciplinary Care of Sarcoma.

Authors:  Inga-Marie Schaefer; Kelvin Hong; Anusha Kalbasi
Journal:  Am Soc Clin Oncol Educ Book       Date:  2020-05

7.  Malignant progression of a peripheral nerve sheath tumor in the setting of rhabdoid tumor predisposition syndrome.

Authors:  Santhosh A Upadhyaya; Rose B McGee; Breelyn A Wilky; Alberto Broniscer
Journal:  Pediatr Blood Cancer       Date:  2018-03-07       Impact factor: 3.167

8.  β-III-spectrin immunohistochemistry as a potential diagnostic tool with high sensitivity for malignant peripheral nerve sheath tumors.

Authors:  Angela C Hirbe; Xiaochun Zhang; Sonika Dahiya; Abigail Godec; John Chrisinger; Yu Tao; Jingqin Luo; David H Gutmann
Journal:  Neuro Oncol       Date:  2018-05-18       Impact factor: 12.300

9.  Reduced H3K27me3 Expression Is Common in Nodular Melanomas of Childhood Associated With Congenital Melanocytic Nevi But Not in Proliferative Nodules.

Authors:  Klaus J Busam; Kara N Shah; Pedram Gerami; Thomas Sitzman; Achim A Jungbluth; Veronica Kinsler
Journal:  Am J Surg Pathol       Date:  2017-03       Impact factor: 6.394

10.  Low-grade Schwann cell neoplasms with leptomeningeal dissemination: clinicopathologic and autopsy findings.

Authors:  Erika F Rodriguez; Jaishri Blakeley; Shannon Langmead; Alessandro Olivi; Anthony Tufaro; Abeer Tabbarah; Gail Berkenblit; Justin M Sacks; Scott D Newsome; Elizabeth Montgomery; Fausto J Rodriguez
Journal:  Hum Pathol       Date:  2016-09-22       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.